Abstract:Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clinical trials. Recently, dual targeting strategy comprising the HDACs component has emerged as an alternative approach for combination therapies. In this perspective, we intend to gather all HDACs-containing dual inhibitors related to cancer therapy published in literature since 2015, classify them into five categories based on targets' biological functions, and discuss the rationale why dual acting agents should work better than combinatorial therapies using two separate drugs. The article discusses the pharmacological aspects of these dual inhibitors, including in vitro biological activities, pharmacokinetic studies, in vivo efficacy studies, as well as available clinical trials. The review of the current status and advances should provide better analysis for future opportunities and challenges of this field.

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

An Overview of HDAC Inhibitors and Their Synthetic Routes.

Targeting histone deacetylases for cancer therapy: Trends and challenges

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

HDAC-targeting epigenetic modulators for cancer immunotherapy

Advances in targeting histone deacetylase for treatment of solid tumors

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

New Development of HDAC Inhibitors As Anti-Cancer Agents

Next-generation of Selective Histone Deacetylase Inhibitors

Advances of histone deacetylases inhibitors as novel anti-cancer agents in clinical study

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

Histone Deacetylase Inhibitors as Anticancer Drugs

Cyclic Peptide Histone Deacetylase Inhibitors

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.